Latest Breaking News On - Development head for duchenne - Page 1 : vimarsana.com

Pfizer Inc. today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy,.

Dan levyFordadistrogene movaparvovec clinical programPfizer incExchange commissionDevelopment head for duchenneNorth star ambulatory assessmentDevelopment headFordadistrogene movaparvovec clinicalBreakthroughs that change patientPfizer newsAnnual reportLooking informationFactors that may affect futureOrphanetj rare